EGFR and central nervous system neoplasm: A striking progression has been the joining of atomic markers such as IDH1/2 transformations, MGMT promoter methylation, EGFR amplification/mutations, and 1p/19q codeletion into the symptomatic criteria for gliomas, as laid out by the WHO CNS tumor classifications.